Sterling Biotech Limited announced unaudited standalone earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales/income from operations was INR 1,006.299 million against INR 1,882.136 million a year ago. Loss from operations before other income and finance costs was INR 573.420 million against INR 271.486 million a year ago.

Loss from ordinary activities after finance costs but before tax was INR 1,337.356 million against INR 1,529.596 million a year ago. Net loss was INR 903.456 million against INR 1,033.296 million a year ago. Diluted loss per share before and after extraordinary items was INR 2.09 against INR 2.39 a year ago.